Literature DB >> 2486844

Suprasternal M-mode echocardiography of the right pulmonary artery as a model for investigation of pulmonary hemodynamics in essential hypertension.

S J Yang, J G Cho, J C Park, J C Kang.   

Abstract

The right pulmonary artery (RPA) dimensions of 85 asymptomatic mild or moderate hypertension (HT) patients, divided into 6 subgroups according to the left ventricular (LV) mass index (125g/m2 BSA) left atrial (LA) dimension index (2.2cm/m2 BSA), and 40 normal subjects were studied utilizing suprasternal M-mode echocardiography in order to examine the consistency of the elevated PA pressure in essential HT and to understand its pathogenesis. The RPA dimension at late diastole, at the end of the right ventricular isovolumic contraction, and at systole in the subgroup of HT without LV hypertrophy and LA enlargement was significantly increased compared with those of the normal group (18.4 +/- 2.8 vs 16.2 +/- 2.3mm, 19.6 +/- 3.0 vs 17.2 +/- 1.3mm, 22.5 +/- 2.5 vs 20.8 +/- 1.9mm, p less than 0.05, respectively) and varied in close correlation with systolic and diastolic BP and the dimension of the aorta. The dimensions in the other 5 subgroups were the same and were not further affected by the LV mass and LA dimension. The above results suggest that elevated systemic BP per se is associated with the dilation of the RPA supposedly caused by increased PA resistance, besides the backward effect of the increased LV and/or LA pressure which may affect the increase of PA pressure.

Entities:  

Mesh:

Year:  1989        PMID: 2486844      PMCID: PMC4534988          DOI: 10.3904/kjim.1989.4.2.148

Source DB:  PubMed          Journal:  Korean J Intern Med        ISSN: 1226-3303            Impact factor:   2.884


  22 in total

1.  Comparison of the effects of pressor and depressor agents and influences on pulmonary and systemic pressures of normotensive and hypertensive subjects.

Authors:  R A NELSON; L G MAY; A BENNETT; M KOBAYASHI; R GREGORY
Journal:  Am Heart J       Date:  1955-08       Impact factor: 4.749

2.  Increased pulmonary vascular resistance with systemic hypertension. Effect of minoxidil and other antihypertensive agents.

Authors:  J M Atkins; H C Mitchell; W A Pettinger
Journal:  Am J Cardiol       Date:  1977-05-26       Impact factor: 2.778

3.  The posterior aortic wall echocardiogram. Its relationship to left atrial volume change.

Authors:  B L Strunk; J W Fitzgerald; M Lipton; R L Popp; W H Barry
Journal:  Circulation       Date:  1976-11       Impact factor: 29.690

4.  Clinical-physiological correlations in the development of hypertensive heart disease.

Authors:  E D Frohlich; R C Tarazi; H P Dustan
Journal:  Circulation       Date:  1971-09       Impact factor: 29.690

Review 5.  Vasopressin as vasopressor.

Authors:  S R Goldsmith
Journal:  Am J Med       Date:  1987-06       Impact factor: 4.965

6.  Right ventricular performance in essential hypertension.

Authors:  J Ferlinz
Journal:  Circulation       Date:  1980-01       Impact factor: 29.690

7.  Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements.

Authors:  D J Sahn; A DeMaria; J Kisslo; A Weyman
Journal:  Circulation       Date:  1978-12       Impact factor: 29.690

8.  Systemic and pulmonary hemodynamic responses to nicardipine during graded ergometric exercise in patients with moderate to severe essential hypertension.

Authors:  R J Cody; S H Kubo; K S Ryman; A Shaknovich; J H Laragh
Journal:  J Am Coll Cardiol       Date:  1987-09       Impact factor: 24.094

9.  Left ventricular function and the distribution of pulmonary and total blood volume in hypertensive and normotensive man.

Authors:  I Mackay; K Nath; M L Watson; W J Hannan; A L Muir
Journal:  Nucl Med Commun       Date:  1984-10       Impact factor: 1.690

10.  Recommendations concerning use of echocardiography in hypertension and general population research.

Authors:  R B Devereux; P R Liebson; M J Horan
Journal:  Hypertension       Date:  1987-02       Impact factor: 10.190

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.